Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Eli Lilly and sent this email to their subscribers on August 22, 2024.

August 22, 2024 10:00 AM EDT

Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference

View this release →

Or click here to view all releases.

Text-only version of this email

Eli Lilly and Company August 22, 2024 10:00 AM EDT Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference View this release → Or click here to view all releases.

Show all

The Latest Emails Sent By Eli Lilly and

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

New Form 8-K for Eli Lilly and Company

New Form 8-K for Eli Lilly and Company

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

More Emails, Deals & Coupons From Eli Lilly and

Lilly confirms date and conference call for third-quarter 2024 financial results announcement

Lilly confirms date and conference call for third-quarter 2024 financial results announcement

Lilly's Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E Ε4 Heterozygotes or Non-Carriers

Lilly's Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E Ε4 Heterozygotes or Non-Carriers

Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies

Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies

Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%

Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%

Stock Quote Notification for Eli Lilly and Company

Stock Quote Notification for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase

Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 4 for Eli Lilly and Company

New Form 10-Q for Eli Lilly and Company

New Form 10-Q for Eli Lilly and Company